Tri Locum Partners LP 13F: Quarter-over-Quarter Portfolio Changes
Tri Locum Partners LP reported a disclosed portfolio value of approximately $813.2 million in its latest SEC Form 13F-HR filing for Q2 2026, up 14.1% quarter on quarter. Over the quarter, the fund initiated 5 new positions, bought more shares in 8 holdings, trimmed 6 holdings, and exited 3 positions.
Tri Locum Partners LP's top buy was a new stake in Ascendis Pharma A/S (ASND) , equal to 8.5% of the disclosed portfolio. Its top sell was Thermo Fisher Scientific INC (TMO) . The fund exited the position completely after it had accounted for 9.1% of the previous portfolio.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| ASCENDIS PHARMA A/S | ASND | 8.5% | History → |
| ENLIVEN THERAPEUTICS INC | ELVN | 5.4% | History → |
| REVOLUTION MEDICINES INC | RVMD | 3.5% | Holders → |
| CYTOKINETICS INC | CYTK | 2.0% | Holders → |
| BETA BIONICS INC | BBNX | 1.0% | Holders → |
Top BuysQ2 2026
The fund's top buys among existing positions in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| AXSOME THERAPEUTICS INC. | AXSM | +5.1% | +253.1% | History → |
| VERTEX PHARMACEUTICALS INC | VRTX | +4.2% | +56.0% | History → |
| JAZZ PHARMACEUTICALS PLC | JAZZ | +2.4% | +39.7% | History → |
| ARGENX SE | ARGX | +1.5% | +31.5% | History → |
| TARSUS PHARMACEUTICALS INC | TARS | +0.1% | +30.0% | Holders → |
| ELI LILLY & CO | LLY | +3.3% | +23.8% | History → |
| DEXCOM INC | DXCM | +0.6% | +17.5% | History → |
| JOHNSON & JOHNSON | JNJ | +-0.9% | +2.5% | History → |
Top SellsQ2 2026
The fund's top sells among positions it retained in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| INTUITIVE SURGICAL INC | ISRG | -7.6% | 68.7% | Holders → |
| DEFINIUM THERAPEUTICS INC | DFTX | -0.0% | 55.9% | Holders → |
| MADRIGAL PHARMACEUTICALS INC | MDGL | -3.1% | 33.9% | History → |
| UNITED THERAPEUTICS CORP DEL | UTHR | -2.7% | 33.2% | Holders → |
| TEVA PHARMACEUTICAL INDS LTD | TEVA | -1.2% | 26.9% | Holders → |
| DIANTHUS THERAPEUTICS INC | DNTH | -0.3% | 17.1% | Holders → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| THERMO FISHER SCIENTIFIC INC | TMO | 9.1% |
| ASCENDIS PHARMA A/S | SYN_04351P101 | 8.2% |
| NUVALENT INC | NUVL | 4.4% |
Net Portfolio Value ChangeQ2 2026
- $0.7BPrior quarter
- $0.8BCurrent quarter
- +$0.1BNet delta
- +14.1%% change
Methodology & FAQ
How Tri Locum Partners LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Tri Locum Partners LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Tri Locum Partners LP buy in Q2 2026?
In Q2 2026, Tri Locum Partners LP initiated 5 new positions (ASCENDIS PHARMA A/S (ASND), ENLIVEN THERAPEUTICS INC (ELVN), REVOLUTION MEDICINES INC (RVMD), CYTOKINETICS INC (CYTK), BETA BIONICS INC (BBNX)); bought more shares of AXSOME THERAPEUTICS INC. (AXSM), VERTEX PHARMACEUTICALS INC (VRTX), JAZZ PHARMACEUTICALS PLC (JAZZ), ARGENX SE (ARGX), TARSUS PHARMACEUTICALS INC (TARS) (the largest 5 of 8 adds).
What stocks did Tri Locum Partners LP sell in Q2 2026?
In Q2 2026, Tri Locum Partners LP fully sold 3 positions (THERMO FISHER SCIENTIFIC INC (TMO), ASCENDIS PHARMA A/S (SYN_04351P101), NUVALENT INC (NUVL)); reduced holdings in INTUITIVE SURGICAL INC (ISRG), DEFINIUM THERAPEUTICS INC (DFTX), MADRIGAL PHARMACEUTICALS INC (MDGL), UNITED THERAPEUTICS CORP DEL (UTHR), TEVA PHARMACEUTICAL INDS LTD (TEVA) (the largest 5 of 6 reductions).
Which positions did Tri Locum Partners LP initiate in Q2 2026?
Tri Locum Partners LP established 5 new positions in Q2 2026: ASCENDIS PHARMA A/S (ASND, 8.5%), ENLIVEN THERAPEUTICS INC (ELVN, 5.4%), REVOLUTION MEDICINES INC (RVMD, 3.5%), CYTOKINETICS INC (CYTK, 2.0%), BETA BIONICS INC (BBNX, 1.0%).
Which existing positions saw the largest allocation increases for Tri Locum Partners LP in Q2 2026?
Of 8 existing positions with share-count increases in Q2 2026, the largest were: AXSOME THERAPEUTICS INC. (AXSM, +5.1% weight, +253.1% shares), VERTEX PHARMACEUTICALS INC (VRTX, +4.2% weight, +56.0% shares), JAZZ PHARMACEUTICALS PLC (JAZZ, +2.4% weight, +39.7% shares), ARGENX SE (ARGX, +1.5% weight, +31.5% shares), TARSUS PHARMACEUTICALS INC (TARS, +0.1% weight, +30.0% shares), ELI LILLY & CO (LLY, +3.3% weight, +23.8% shares), DEXCOM INC (DXCM, +0.6% weight, +17.5% shares), JOHNSON & JOHNSON (JNJ, +-0.9% weight, +2.5% shares).
Which positions did Tri Locum Partners LP fully exit in Q2 2026?
Tri Locum Partners LP fully exited 3 positions in Q2 2026: THERMO FISHER SCIENTIFIC INC (TMO, last-reported weight 9.1%), ASCENDIS PHARMA A/S (SYN_04351P101, last-reported weight 8.2%), NUVALENT INC (NUVL, last-reported weight 4.4%).
Which existing positions saw the largest allocation reductions for Tri Locum Partners LP in Q2 2026?
Of 6 existing positions with share-count reductions in Q2 2026, the largest were: INTUITIVE SURGICAL INC (ISRG, -7.6% weight, -68.7% shares), DEFINIUM THERAPEUTICS INC (DFTX, -0.0% weight, -55.9% shares), MADRIGAL PHARMACEUTICALS INC (MDGL, -3.1% weight, -33.9% shares), UNITED THERAPEUTICS CORP DEL (UTHR, -2.7% weight, -33.2% shares), TEVA PHARMACEUTICAL INDS LTD (TEVA, -1.2% weight, -26.9% shares), DIANTHUS THERAPEUTICS INC (DNTH, -0.3% weight, -17.1% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.